Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 170 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Myringotomy
Interventions
Dexmedetomidine
Drug
Lead sponsor
Martin Mueller
Other
Eligibility
1 Year to 10 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Alzheimer's Disease
Interventions
Prazosin, Placebo
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Dementia, Alzheimer's Disease
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
14
States / cities
Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more
Conditions
Agitation, Alzheimer Disease
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
53
States / cities
Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 46 more
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Conditions
Dementia, Alzheimer Disease, Vascular Dementia, Frontotemporal Dementia, Lewy Body Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Conditions
Acute Respiratory Failure, Encephalopathy, ARDS, Sepsis, Critical Illness
Interventions
Exersides
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Burlington, Vermont
Conditions
Agitation
Interventions
12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo DMTS Patches, Placebo - 2 Placebo DMTS Patches
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Daytona Beach, Florida • Miami, Florida • St. Petersburg, Florida + 3 more
Conditions
Agitation
Interventions
Asenapine, Placebo
Drug
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Syracuse, New York
Completed Not applicable Interventional Results available

Actigraphic Analysis of Treatment Response

NCT00723580
Conditions
Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
Interventions
risperidone
Drug
Lead sponsor
Child Psychopharmacology Institute
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
46
States / cities
Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Peer Support in the ED (PCORI)

NCT06556069
Conditions
Psychomotor Agitation, Behavioral Disorder
Interventions
Peer-Support Enhanced Agitation Code Team (PACT)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
57,870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Emergence Agitation
Interventions
Depth of anesthesia
Other
Lead sponsor
Duke University
Other
Eligibility
2 Years to 8 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Agitation,Psychomotor
Interventions
Loxapine 10 MG
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Peoria, Arizona • Walnut Creek, California • Bonita Springs, Florida + 13 more
Conditions
Alzheimer's Disease, Dementia
Interventions
Risperidone, Gabapentin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Menlo Park, California
Completed Not applicable Interventional Accepts healthy volunteers

Methodology Issues in a Tailored Light Treatment for Persons With Dementia

NCT01816152
Conditions
Sleep Disturbances, Depression
Interventions
Tailored Active intervention, Inactive intervention
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Albany, New York • New York, New York
Conditions
Alzheimer's Disease
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 91 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Alzheimer's Disease, Dementia
Interventions
high-intensity light therapy
Device
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
55 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Butner, North Carolina
Conditions
Alzheimer's Disease
Interventions
Group 1 ELND005, Group 2 ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Imperial, California • Lakewood, California • Long Beach, California + 21 more
Conditions
Alzheimer Disease
Interventions
Trazodone, Haloperidol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 12 more
Completed Phase 4 Interventional Results available

Propofol in Emergence Agitation

NCT00535613
Conditions
Emergence Agitation
Interventions
Propofol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Months to 6 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Bellflower, California • Cerritos, California • Culver City, California + 19 more